Design, synthesis, and evaluation of novel immunomodulatory small molecules targeting the CD40–CD154 costimulatory protein-protein interaction

Damir Bojadzic, Jinshui Chen, Oscar Alcazar, Peter Buchwald

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We report the design, synthesis, and testing of novel small-molecule compounds targeting the CD40–CD154 (CD40L) costimulatory interaction for immunomodulatory purposes. This protein-protein interaction (PPI) is a TNF-superfamily (TNFSF) costimulatory interaction that is an important therapeutic target since it plays crucial roles in the activation of T cell responses, and there is resurgent interest in its modulation with several biologics in development. However, this interaction, just as all other PPIs, is difficult to target by small molecules. Following up on our previous work, we have now identified novel compounds such as DRI-C21091 or DRI-C21095 that show activity (IC50) in the high nanomolar to low micromolar range in the binding inhibition assay and more than thirty-fold selectivity versus other TNFSF PPIs including OX40–OX40L, BAFFR-BAFF, and TNF-R1-TNFα. Protein thermal shift (differential scanning fluorimetry) assays indicate CD154 and not CD40 as the binding partner. Activity has also been confirmed in cell assays and in a mouse model (alloantigen-induced T cell expansion in a draining lymph node). Our results expand the chemical space of identified small-molecule CD40–CD154 costimulatory inhibitors and provide lead structures that have the potential to be developed as orally bioavailable immunomodulatory therapeutics that are safer and less immunogenic than corresponding biologics.

Original languageEnglish (US)
Article number1153
JournalMolecules
Volume23
Issue number5
DOIs
StatePublished - Jan 1 2018

Fingerprint

Assays
T-cells
plan position indicators
Biological Products
proteins
Molecules
evaluation
synthesis
T-Lymphocytes
molecules
Fluorometry
CD40 Ligand
Proteins
Isoantigens
interactions
Inhibitory Concentration 50
lymphatic system
Hot Temperature
drainage
Lymph Nodes

Keywords

  • Costimulation
  • Drug design
  • Immune modulation
  • Protein-protein interaction
  • Small molecule
  • TNF superfamily

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Cite this

Design, synthesis, and evaluation of novel immunomodulatory small molecules targeting the CD40–CD154 costimulatory protein-protein interaction. / Bojadzic, Damir; Chen, Jinshui; Alcazar, Oscar; Buchwald, Peter.

In: Molecules, Vol. 23, No. 5, 1153, 01.01.2018.

Research output: Contribution to journalArticle

@article{8fb9a625fee14800926786bdf47d156d,
title = "Design, synthesis, and evaluation of novel immunomodulatory small molecules targeting the CD40–CD154 costimulatory protein-protein interaction",
abstract = "We report the design, synthesis, and testing of novel small-molecule compounds targeting the CD40–CD154 (CD40L) costimulatory interaction for immunomodulatory purposes. This protein-protein interaction (PPI) is a TNF-superfamily (TNFSF) costimulatory interaction that is an important therapeutic target since it plays crucial roles in the activation of T cell responses, and there is resurgent interest in its modulation with several biologics in development. However, this interaction, just as all other PPIs, is difficult to target by small molecules. Following up on our previous work, we have now identified novel compounds such as DRI-C21091 or DRI-C21095 that show activity (IC50) in the high nanomolar to low micromolar range in the binding inhibition assay and more than thirty-fold selectivity versus other TNFSF PPIs including OX40–OX40L, BAFFR-BAFF, and TNF-R1-TNFα. Protein thermal shift (differential scanning fluorimetry) assays indicate CD154 and not CD40 as the binding partner. Activity has also been confirmed in cell assays and in a mouse model (alloantigen-induced T cell expansion in a draining lymph node). Our results expand the chemical space of identified small-molecule CD40–CD154 costimulatory inhibitors and provide lead structures that have the potential to be developed as orally bioavailable immunomodulatory therapeutics that are safer and less immunogenic than corresponding biologics.",
keywords = "Costimulation, Drug design, Immune modulation, Protein-protein interaction, Small molecule, TNF superfamily",
author = "Damir Bojadzic and Jinshui Chen and Oscar Alcazar and Peter Buchwald",
year = "2018",
month = "1",
day = "1",
doi = "10.3390/molecules23051153",
language = "English (US)",
volume = "23",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - Design, synthesis, and evaluation of novel immunomodulatory small molecules targeting the CD40–CD154 costimulatory protein-protein interaction

AU - Bojadzic, Damir

AU - Chen, Jinshui

AU - Alcazar, Oscar

AU - Buchwald, Peter

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We report the design, synthesis, and testing of novel small-molecule compounds targeting the CD40–CD154 (CD40L) costimulatory interaction for immunomodulatory purposes. This protein-protein interaction (PPI) is a TNF-superfamily (TNFSF) costimulatory interaction that is an important therapeutic target since it plays crucial roles in the activation of T cell responses, and there is resurgent interest in its modulation with several biologics in development. However, this interaction, just as all other PPIs, is difficult to target by small molecules. Following up on our previous work, we have now identified novel compounds such as DRI-C21091 or DRI-C21095 that show activity (IC50) in the high nanomolar to low micromolar range in the binding inhibition assay and more than thirty-fold selectivity versus other TNFSF PPIs including OX40–OX40L, BAFFR-BAFF, and TNF-R1-TNFα. Protein thermal shift (differential scanning fluorimetry) assays indicate CD154 and not CD40 as the binding partner. Activity has also been confirmed in cell assays and in a mouse model (alloantigen-induced T cell expansion in a draining lymph node). Our results expand the chemical space of identified small-molecule CD40–CD154 costimulatory inhibitors and provide lead structures that have the potential to be developed as orally bioavailable immunomodulatory therapeutics that are safer and less immunogenic than corresponding biologics.

AB - We report the design, synthesis, and testing of novel small-molecule compounds targeting the CD40–CD154 (CD40L) costimulatory interaction for immunomodulatory purposes. This protein-protein interaction (PPI) is a TNF-superfamily (TNFSF) costimulatory interaction that is an important therapeutic target since it plays crucial roles in the activation of T cell responses, and there is resurgent interest in its modulation with several biologics in development. However, this interaction, just as all other PPIs, is difficult to target by small molecules. Following up on our previous work, we have now identified novel compounds such as DRI-C21091 or DRI-C21095 that show activity (IC50) in the high nanomolar to low micromolar range in the binding inhibition assay and more than thirty-fold selectivity versus other TNFSF PPIs including OX40–OX40L, BAFFR-BAFF, and TNF-R1-TNFα. Protein thermal shift (differential scanning fluorimetry) assays indicate CD154 and not CD40 as the binding partner. Activity has also been confirmed in cell assays and in a mouse model (alloantigen-induced T cell expansion in a draining lymph node). Our results expand the chemical space of identified small-molecule CD40–CD154 costimulatory inhibitors and provide lead structures that have the potential to be developed as orally bioavailable immunomodulatory therapeutics that are safer and less immunogenic than corresponding biologics.

KW - Costimulation

KW - Drug design

KW - Immune modulation

KW - Protein-protein interaction

KW - Small molecule

KW - TNF superfamily

UR - http://www.scopus.com/inward/record.url?scp=85047187635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047187635&partnerID=8YFLogxK

U2 - 10.3390/molecules23051153

DO - 10.3390/molecules23051153

M3 - Article

C2 - 29751636

AN - SCOPUS:85047187635

VL - 23

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 5

M1 - 1153

ER -